TY - JOUR
T1 - Significant variation in performance does not reflect the effectiveness of the cervical cancer screening programme in Finland
AU - Kotaniemi-Talonen, Laura
AU - Nieminen, Pekka
AU - Hakama, Matti
AU - Seppänen, Johanna
AU - Ikkala, Jorma
AU - Martikainen, Jorma
AU - Tarkkanen, Jussi
AU - Toivonen, Terttu
AU - Anttila, Ahti
PY - 2007
Y1 - 2007
N2 - AIM: To characterise the variation in performance indicators of the Finnish cervical screening programme by screening laboratory and to assess whether the performance affects cervical cancer incidence.METHODS: Cervical cancer screening data from 1999 to 2003 from six well-established laboratories were used to analyse rates for follow-up recommendations, referrals and histologically confirmed dysplastic lesions. Laboratory-specific cervical cancer incidences for 1954-2003 were assessed using the cancer registry files.RESULTS: Differences in follow-up recommendations were up to 3.1-fold and 2.2-fold in referrals; differences in the rates for CIN1, CIN2 and CIN3+ were up to 4.5-, 4.7-, and 1.5-fold, respectively. Pre-screening incidence rates for cervical cancer varied 1.5-fold by laboratory, with no major differences in the incidence trends since the onset of screening.CONCLUSION: The performance of a cervical screening programme differs by screening laboratory but does not materially affect the overall programme effectiveness. This leads to variation in cost-effectiveness and probably in avoidable adverse effects. In cervical cancer screening studies, the outcome should be selected as closely as possible to the true measure of programme effectiveness, prevented invasive cervical cancers and subsequent deaths.
AB - AIM: To characterise the variation in performance indicators of the Finnish cervical screening programme by screening laboratory and to assess whether the performance affects cervical cancer incidence.METHODS: Cervical cancer screening data from 1999 to 2003 from six well-established laboratories were used to analyse rates for follow-up recommendations, referrals and histologically confirmed dysplastic lesions. Laboratory-specific cervical cancer incidences for 1954-2003 were assessed using the cancer registry files.RESULTS: Differences in follow-up recommendations were up to 3.1-fold and 2.2-fold in referrals; differences in the rates for CIN1, CIN2 and CIN3+ were up to 4.5-, 4.7-, and 1.5-fold, respectively. Pre-screening incidence rates for cervical cancer varied 1.5-fold by laboratory, with no major differences in the incidence trends since the onset of screening.CONCLUSION: The performance of a cervical screening programme differs by screening laboratory but does not materially affect the overall programme effectiveness. This leads to variation in cost-effectiveness and probably in avoidable adverse effects. In cervical cancer screening studies, the outcome should be selected as closely as possible to the true measure of programme effectiveness, prevented invasive cervical cancers and subsequent deaths.
KW - Adult
KW - Cervical Intraepithelial Neoplasia/epidemiology
KW - Clinical Laboratory Techniques/standards
KW - Female
KW - Finland/epidemiology
KW - Humans
KW - Incidence
KW - Mass Screening/standards
KW - Middle Aged
KW - Predictive Value of Tests
KW - Randomized Controlled Trials as Topic
KW - Registries
KW - Sensitivity and Specificity
KW - Uterine Cervical Neoplasms/epidemiology
KW - Vaginal Smears/standards
U2 - 10.1016/j.ejca.2006.08.026
DO - 10.1016/j.ejca.2006.08.026
M3 - Article
C2 - 17049228
SN - 0959-8049
VL - 43
SP - 169
EP - 174
JO - EUROPEAN JOURNAL OF CANCER
JF - EUROPEAN JOURNAL OF CANCER
IS - 1
ER -